News

  During the 4 days of the Congress, about 6,000 participants from around the world: psychiatrists, neurobiologists and neurologists will discuss the most important scientific reports on diagnostics and brain treatment, from baseline studies to clinical development. During the Congress, the Clinical Department representatives will present the results in a poster session which will takeRead more »

Celon Pharma became the leader of a European training project concerning the so-called hard skills, addressed to scientists, students, start-ups and entrepreneurs from all over Europe. The project is implemented in cooperation with the Medical University in Łódź, University of Navarra and Universidade de Evora, within the EIT Health network. Maciej Wieczorek, CEO of CelonRead more »

By way of decisions of the Chief Pharmaceutical Inspectorate of 6/06/2019, the following drug batches mentioned therein – Valzek 80mg and Valzek 160mg – were re-approved for marketing, as a result of confirming their compliance with quality requirements for the applicable substance valsartan, determined by the regulators. Based on these decisions, batches of Valzek markedRead more »

The Company’s representatives will participate in the BIO International Convention 2019, an international convention which attracts over 16.000 biotechnology and pharmacy leaders each year. The conference allows for networking and collaboration in the field of drug development. Maciej Wieczorek, CEO of Celon Pharma S.A.: We can confirm the growing interest in our projects in theRead more »

On 12 April 2019, the Food and Drug Administration (FDA) allowed the marketing of erdafitinib in urinary tract cancer treatment. This decision confirms the great potential of FGFR inhibitors in various solid cancers with FGFR aberrations and proves the recognition of this class medicines as new tools in advanced solid cancers treatment. Celon Pharma S.A.Read more »

Celon Pharma S.A. representatives took part in the 27th European Congress of Psychiatry, EPA 2019, which was held from 6 to 9 April 2019 in Warsaw. Over 3,500 participants from all over the world took part in workshops, lectures and presentations devoted to the latest achievements in neuropsychiatry. The European Psychiatric Association is the biggestRead more »

Representatives of the Company’s Management Board: Bogdan Manowski – Director for Business Development and dr Maciej Wieczorek – President of the Management Board, spoke at the GPW Innovation Day conference which is a meeting of investors with innovative companies including companies from biotechnology sector. During their presentation, the Management Board presented the current status ofRead more »

Three active clinical programmes, including two regarding the most dynamic therapeutic area from the point of view of the next decade, which is neuropsychiatry, advanced pre-clinical development of drug candidates with innovative potential, continuation of construction of the largest Centre for Science and Research in Central and Eastern Europe together with a great financial resultRead more »

Dr Maciej Wieczorek, President of the Management Board at Celon Pharma S.A., was among the 100 most influential people of the Polish health care system according to “Puls Medycyny”. For 16 years, “Puls Medycyny” has honoured those who have a particular impact on the development of the Polish medicine and, for 4 years, those whoRead more »

International experts cooperating with the FDA have confirmed the efficacy and safety of eskatemine in treatment of unipolar, treatment-resistant depression, which might become the first cutting edge therapy for patients since the last innovation introduced 35 years ago. Celon Pharma develops this substance in two indications and is currently conducting phase II clinical trials. OnRead more »